Averion Appoints Glenn E. Deegan Vice President and General Counsel.

BOSTON -- Averion International Corp. (OTCBB:AVRO), a clinical research organization (CRO) specializing in oncology, medical devices, dermatology and nephrology, today announced the appointment of Glenn E. Deegan as vice president and general counsel. Mr. Deegan's responsibilities will include directing all Company legal matters including compliance with securities regulations, acquisitions and partnering activities, and corporate governance matters.

"Glenn is ideally suited to fill our general counsel position based on his combined legal, healthcare and public company experience," said Philip Lavin, PhD, Averion International chief executive officer. "We expect to call on Glenn's expertise as we continue integration activities, pursue a multi-prong growth strategy that includes international expansion through acquisition and partnerships, and meet public company compliance regulations."

Glenn brings to Averion 15 years experience in managing complex legal and business matters including: securities and regulatory issues; corporate finance and transactions; intellectual property; and employment issues. Most recently, Mr. Deegan served for six years as vice president and general counsel at MacroChem Corporation, a publicly traded biopharmaceutical company, where he was responsible for all company legal matters. Previously, he served as assistant general counsel at Summit Autonomous (formerly Summit Technology, Inc.), a publicly traded manufacturer of ophthalmic laser systems with revenues in excess of $100 million. Prior to that, he practiced law at several law firms where he represented clients on a broad range of litigation matters.

Mr. Deegan received his J.D., cum laude, from Boston College Law School and his bachelor's of science in engineering/physics/systems, magna cum laude, from Providence College. He is a member of the American, Boston and Rhode Island Bar Associations.

About Averion International Corp.

Averion International Corp. is a full service clinical research organization (CRO) that provides clinical research, regulatory compliance and validation services to the pharmaceutical, biotechnology and medical device/diagnostic industries. The Company has a therapeutic focus in oncology, dermatology, nephrology and medical devices. Averion's clinical research core competencies are in FDA and product registration support, site selection, project management, medical and site monitoring, data management, biometrics, pharmacovigilance, medical writing, and full clinical trial management services throughout the clinical trial's lifecycle. The Company has supported FDA approvals for products in many therapeutic areas including: oncology, medical devices, dermatology, nephrology and cardiology.

Averion provides oncology-specific clinical research services through its Millennix Oncology branded service line.

Averion IT&E International Division offers global regulatory compliance and validation services throughout the product development lifecycle. The Company's team of industry veterans utilizes the latest tools and procedures to help its clients move quickly and effectively from drug development through the FDA approval process. Consulting services include regulatory planning, providing skilled personnel for development operations, enterprise software and training to manage data and ensure FDA compliance and validation of new pharmaceutical manufacturing facilities. (http://www.iteinternational.com)

Averion is headquartered in Southborough, Mass. and has additional U.S. office locations in New York, Philadelphia and California, as well as European offices in Germany, United Kingdom, Austria and Poland. For more information, please visit our Web site at www.averionintl.com.

Forward-Looking Statement 

Included in this press release are "forward-looking statements." Statements in this press release that are forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates" and similar expressions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission, including its most recent 10-KSB. The Company is not under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.